Literature DB >> 24002705

Cyclin A1 is a transcriptional target of PITX2 and overexpressed in papillary thyroid carcinoma.

Yan Liu1, Yue Huang, Guo-Zhang Zhu.   

Abstract

Physiological expression of cyclin A1, a unique cell cycle regulator essential for spermatogenesis, is predominantly restricted in male germ cells. Outstandingly, previous studies have also demonstrated the abnormal expression of cyclin A1 in various human tumors. How male germ cell-specific cyclin A1 is transcriptionally activated in tumor cells, however, is elusive. To begin to understand the molecular mechanisms governing the ectopic expression of cyclin A1, we searched for transcription factors and cis-regulatory DNA elements. We found that overexpression of PITX2, a paired-like homeodomain transcription factor and a downstream effector of Wnt/β-catenin signaling, resulted in upregulation of cyclin A1 in HEK293 cells and TPC-1 thyroid cancer cells. On the other hand, PITX2 knockdown in TPC-1 cells caused reduced cyclin A1. Promoter reporter assays with a series of deletion constructs determined that the DNA element from -102 to -96 bp of the cyclin A1 promoter is responsible for PITX2-induced gene expression. The result of chromatin immunoprecipitation revealed the occupancy of PITX2 on the cyclin A1 promoter. Taken together, these findings demonstrate that cyclin A1 is a transcriptional target of PITX2. Consistently, our immunohistochemistry result showed up-regulation of cyclin A1 in human papillary thyroid carcinoma, where overexpressed PITX2 has been endorsed in our recent report. Thus, our study provides new evidence on the regulation of cyclin A1 gene expression and offers a PITX2-cycin A1 pathway for cell cycle regulation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24002705     DOI: 10.1007/s11010-013-1801-9

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  31 in total

Review 1.  Recycling the cell cycle: cyclins revisited.

Authors:  Andrew W Murray
Journal:  Cell       Date:  2004-01-23       Impact factor: 41.582

2.  Distinct properties of cyclin-dependent kinase complexes containing cyclin A1 and cyclin A2.

Authors:  Ayesha R Joshi; Vaidehi Jobanputra; Karen M Lele; Debra J Wolgemuth
Journal:  Biochem Biophys Res Commun       Date:  2008-12-03       Impact factor: 3.575

3.  Function of Rieger syndrome gene in left-right asymmetry and craniofacial development.

Authors:  M F Lu; C Pressman; R Dyer; R L Johnson; J F Martin
Journal:  Nature       Date:  1999-09-16       Impact factor: 49.962

4.  Pituitary homeobox 2 (PITX2) promotes thyroid carcinogenesis by activation of cyclin D2.

Authors:  Yue Huang; Celine J Guigon; Jun Fan; Sheue-yann Cheng; Guo-Zhang Zhu
Journal:  Cell Cycle       Date:  2010-04-01       Impact factor: 4.534

5.  A molecular basis for differential developmental anomalies in Axenfeld-Rieger syndrome.

Authors:  Herbert M Espinoza; Carol J Cox; Elena V Semina; Brad A Amendt
Journal:  Hum Mol Genet       Date:  2002-04-01       Impact factor: 6.150

6.  Methylation of the cyclin A1 promoter correlates with gene silencing in somatic cell lines, while tissue-specific expression of cyclin A1 is methylation independent.

Authors:  C Müller; C Readhead; S Diederichs; G Idos; R Yang; N Tidow; H Serve; W E Berdel; H P Koeffler
Journal:  Mol Cell Biol       Date:  2000-05       Impact factor: 4.272

7.  PITX2: a promising predictive biomarker of patients' prognosis and chemoradioresistance in esophageal squamous cell carcinoma.

Authors:  Jia-Xing Zhang; Zhu-Ting Tong; Lin Yang; Fan Wang; Hui-Ping Chai; Fan Zhang; Ming-Ran Xie; An-Li Zhang; Li-Ming Wu; Hao Hong; Lv Yin; Hao Wang; Hong-Yan Wang; Yuan Zhao
Journal:  Int J Cancer       Date:  2012-11-26       Impact factor: 7.396

8.  Identification of a Wnt/Dvl/beta-Catenin --> Pitx2 pathway mediating cell-type-specific proliferation during development.

Authors:  Chrissa Kioussi; Paola Briata; Sung Hee Baek; David W Rose; Natasha S Hamblet; Thomas Herman; Kenneth A Ohgi; Chijen Lin; Anatoli Gleiberman; Jianbo Wang; Veronique Brault; Pilar Ruiz-Lozano; H D Nguyen; Rolf Kemler; Christopher K Glass; Anthony Wynshaw-Boris; Michael G Rosenfeld
Journal:  Cell       Date:  2002-11-27       Impact factor: 41.582

9.  Dosage requirement of Pitx2 for development of multiple organs.

Authors:  P J Gage; H Suh; S A Camper
Journal:  Development       Date:  1999-10       Impact factor: 6.868

10.  Pitx2c patterns anterior myocardium and aortic arch vessels and is required for local cell movement into atrioventricular cushions.

Authors:  Chengyu Liu; Wei Liu; Jennifer Palie; Mei Fang Lu; Nigel A Brown; James F Martin
Journal:  Development       Date:  2002-11       Impact factor: 6.868

View more
  12 in total

1.  p27Kip1 represses the Pitx2-mediated expression of p21Cip1 and regulates DNA replication during cell cycle progression.

Authors:  E Gallastegui; A Biçer; S Orlando; A Besson; M J Pujol; O Bachs
Journal:  Oncogene       Date:  2016-06-06       Impact factor: 9.867

Review 2.  Pitx genes in development and disease.

Authors:  Thai Q Tran; Chrissa Kioussi
Journal:  Cell Mol Life Sci       Date:  2021-04-12       Impact factor: 9.261

3.  PITX2 associates with PTIP-containing histone H3 lysine 4 methyltransferase complex.

Authors:  Yan Liu; Yue Huang; Jun Fan; Guo-Zhang Zhu
Journal:  Biochem Biophys Res Commun       Date:  2014-01-31       Impact factor: 3.575

4.  A Limited Role for the Cell Cycle Regulator Cyclin A1 in Murine Leukemogenesis.

Authors:  Nicole Bäumer; Sebastian Bäumer; Miriam Haak; Steffen Koschmieder; Kai Schönig; Wolfgang E Berdel; Carsten Müller-Tidow
Journal:  PLoS One       Date:  2015-06-16       Impact factor: 3.240

5.  Clinical performance validation of PITX2 DNA methylation as prognostic biomarker in patients with head and neck squamous cell carcinoma.

Authors:  Verena Sailer; Heidrun Gevensleben; Joern Dietrich; Diane Goltz; Glen Kristiansen; Friedrich Bootz; Dimo Dietrich
Journal:  PLoS One       Date:  2017-06-15       Impact factor: 3.240

6.  PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients.

Authors:  Magdalena Absmaier; Rudolf Napieralski; Tibor Schuster; Michaela Aubele; Axel Walch; Viktor Magdolen; Julia Dorn; Eva Gross; Nadia Harbeck; Aurelia Noske; Marion Kiechle; Manfred Schmitt
Journal:  Int J Oncol       Date:  2018-01-08       Impact factor: 5.650

7.  Distinct co-expression networks using multi-omic data reveal novel interventional targets in HPV-positive and negative head-and-neck squamous cell cancer.

Authors:  Raquel L Costa; Mariana Boroni; Marcelo A Soares
Journal:  Sci Rep       Date:  2018-10-15       Impact factor: 4.379

8.  ZYG11A serves as an oncogene in non-small cell lung cancer and influences CCNE1 expression.

Authors:  Xin Wang; Qi Sun; Chen Chen; Rong Yin; Xing Huang; Xuan Wang; Run Shi; Lin Xu; Binhui Ren
Journal:  Oncotarget       Date:  2016-02-16

9.  Smad4-dependent suppressor pituitary homeobox 2 promotes PPP2R2A-mediated inhibition of Akt pathway in pancreatic cancer.

Authors:  Qi Wang; Juanjuan Li; Wei Wu; Ruizhe Shen; He Jiang; Yuting Qian; Yanping Tang; Tingting Bai; Sheng Wu; Lumin Wei; Yi Zang; Ji Zhang; Lifu Wang
Journal:  Oncotarget       Date:  2016-03-08

10.  PITX2 and PANCR DNA methylation predicts overall survival in patients with head and neck squamous cell carcinoma.

Authors:  Verena Sailer; Emily Eva Holmes; Heidrun Gevensleben; Diane Goltz; Freya Dröge; Luka de Vos; Alina Franzen; Friederike Schröck; Friedrich Bootz; Glen Kristiansen; Andreas Schröck; Dimo Dietrich
Journal:  Oncotarget       Date:  2016-11-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.